Detailed Information on Publication Record
2013
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries.
PAGANO, Livio, Oliver A. CORNELY, Alessandro BUSCA, Morena CAIRA, Simone CESARO et. al.Basic information
Original name
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries.
Authors
PAGANO, Livio (380 Italy), Oliver A. CORNELY (276 Germany), Alessandro BUSCA (380 Italy), Morena CAIRA (380 Italy), Simone CESARO (380 Italy), Cristiana GASBARRINO (380 Italy), Corrado GIRMENIA (380 Italy), Werner J. HEINZ (276 Germany), Raoul HERBRECHT (250 France), Cornelia LASS-FLÖRL (40 Austria), Annamaria NOSARI (380 Italy), Leonardo POTENZA (380 Italy), Zdeněk RÁČIL (203 Czech Republic, guarantor, belonging to the institution), Volker RICKERTS (276 Germany), Donald C. SHEPPARD (124 Canada), Arne SIMON (276 Germany), Andrew J. ULLMAN (276 Germany), Caterina Giovanna VALENTINI (380 Italy), Jörg Janne VEHRESCHILD (276 Germany), Anna CANDONI (380 Italy) and Maria J.G.T. VEHRESCHILD (276 Germany)
Edition
Haematologica, Pavia, ITALY, Ferrata Storti Foundation, 2013, 0390-6078
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
Italy
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 5.868
RIV identification code
RIV/00216224:14740/13:00069044
Organization unit
Central European Institute of Technology
UT WoS
000328543400002
Keywords in English
posaconazole; lipid fomulations of amphotericin B; Mucormycosis; combination therapy; invasive fungal infections; hematological malignancies
Tags
International impact, Reviewed
Změněno: 28/4/2014 16:01, Olga Křížová
Abstract
V originále
Our case series may have been subject to selection bias, as only those patients who survived long enough to receive a combination therapy were included. However, since interventional trials on this question are unlikely to be performed any time soon, data from registries remain the only available source of structured information on the treatment of mucormycosis. In conclusion, our analysis suggests that a combined antifungal treatment with Lip-AmB+POS may be considered in patients with very aggressive forms of IM.